Merck and Daiichi Sankyo Initiate Phase 1b/2 Clinical Trial of Gocatamig and I-DXd Combination for Small Cell Lung Cancer
Clinical Background and Design of the Next-Generation Combination Therapy
MSD (Merck & Co.) and Daiichi Sankyo have initiated a Phase 1b/2 clinical trial (NCT07227597) to revolutionize the treatment of extensive-stage small cell lung cancer (ES-SCLC) in the first-line setting. This study aims to overcome the limitations of the current standard of care (SOC), which involves a combination of conventional chemotherapy and immune checkpoint inhibitors, by combining Gocatamig and I-DXd to maximize therapeutic synergy. The trial, which commenced on January 29, 2026, is currently in the global patient recruitment phase and is designed to evaluate the safety, tolerability, and objective response rate (ORR) in a total of 170 patients. Participants will be assigned to four treatment arms based on their prior treatment history, allowing for a direct comparison of treatment efficacy against the standard of care.
Mechanism of Action and Clinical Innovation of the Gocatamig and I-DXd Combination
Gocatamig (MK-6070) is a tri-specific T-cell engager that targets the DLL3 (Delta-like ligand 3) protein, which is overexpressed on the surface of small cell lung cancer cells. It activates the patient's immune system to induce an attack on cancer cells. The combination with I-DXd (MK-2400), an antibody-drug conjugate (ADC) targeting B7-H3, allows for the precise delivery of the cytotoxic payload, deruxtecan (DXd), into cancer cells, resulting in direct cell death. This combination of a T-cell engager with sustained cancer cell recognition and the potent cytotoxic activity of an ADC creates a synergistic mechanism that can target the tumor microenvironment in multiple ways. This approach can effectively inhibit drug resistance, which is often observed with single-agent therapies, and may lead to improved survival rates.
Changes in the Global Small Cell Lung Cancer Market and Competitive Landscape
The global small cell lung cancer (SCLC) market is a high-value area with significant growth potential, projected to increase from approximately $3 billion in 2026 to over $20 billion by 2035. Currently, Amgen's DLL3-targeting immune checkpoint inhibitor, Imdelltra (tarlatamab), has achieved market leadership with its FDA full approval in November 2025. In this competitive environment, Daiichi Sankyo and MSD are proactively initiating a Phase 1b/2 trial of the Gocatamig and I-DXd combination, in addition to pursuing the BLA approval (PDUFA target action date of October 10, 2026) for I-DXd as a single agent, to differentiate themselves in the market. If the Gocatamig and I-DXd combination demonstrates superior data, it has the potential to rapidly establish itself as a first-line standard of care, addressing the limitations of existing Imdelltra monotherapy.
Strategic Collaboration and Financial Impact of the Two Big Pharma Companies
This combination trial demonstrates the tangible research成果 of the multi-billion dollar global oncology alliance established by the two pharmaceutical giants. MSD acquired Harpoon Therapeutics in early 2024 for $680 million, bringing Gocatamig into its pipeline, and subsequently entered into a global co-development agreement with Daiichi Sankyo in August, with an upfront payment of $170 million, to strengthen their partnership. I-DXd was also included in the $22 billion (including a $4 billion upfront payment) co-development agreement for three ADCs signed between the two companies in October 2023, creating significant financial interests for both companies. The results of this trial will be a key factor in determining the future value of the next-generation oncology portfolio and the rate at which the two companies will receive large milestone payments.
This study serves as a key indicator for evaluating the value of MSD and Daiichi Sankyo's core pipeline assets for long-term market share expansion in the global small cell lung cancer (SCLC) market, which is projected to grow from $3 billion in 2026 to over $20 billion by 2035. In the short term, it complements the commercial performance of I-DXd, a B7-H3-targeting ADC, which is expected to receive an FDA PDUFA decision on October 10, 2026. In the medium to long term, it establishes a Phase 1b/2 combination strategy with Gocatamig, a DLL3-targeting tri-specific T-cell engager, to compete with Amgen's Imdelltra. From the perspective of researchers and industry experts, this study represents a leading milestone in demonstrating whether the combination of DLL3 and B7-H3, two promising targets, can overcome resistance to conventional chemotherapy and immune checkpoint inhibitor standard-of-care therapies. Given the existing $22 billion ADC partnership and the additional $170 million Gocatamig co-development agreement, this study is a critical indicator for investors, as it will determine the achievement of financial milestones and demonstrate the synergy of the two companies' new drug research and development capabilities.
Source: ClinicalTrials.gov (api_ct)